EGFR and non-small cell lung carcinoma: Recent research has identified key carcinogenic drivers in NSCLC, particularly activating mutations in the epidermal growth factor receptor (EGFR) gene, which confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and osimertinib [5, 6].